Mendelian, a London-based startup founded by Peter Fish, is revolutionizing healthcare by prioritizing rare disease identification with their groundbreaking platform, MendelScan. With $2.5M raised, Mendelian is on a mission to help doctors identify and treat rare diseases early on, saving lives and improving patient care. While they have yet to reveal their investors, Mendelian's team is committed to building a future where every patient population can expect the right treatment, from the right specialist, at the right time.

Mendelian's strength lies in their deep knowledge of rare diseases and their ability to bring timely patient insights to primary care. They are helping to end the diagnostic odyssey that many rare disease patients face by providing doctors with the tools they need to identify these diseases quickly and accurately. By doing so, Mendelian is ensuring that patients receive the right treatment as soon as possible, leading to better outcomes and a higher quality of life. With MendelScan, Mendelian is making a significant impact in the healthcare industry, and their innovative platform has the potential to transform the way we approach rare disease diagnosis and treatment.